Assessment of Selected Clinical Chemistry Analyses Among Hypertensive Patient on Follow-Up and Non Hypertensive Control Group: A Comparative Cross Sectional Study at Wallaga University Referral Hospital

Abstract

Background: Hypertension (HTN) is a chronic disease characterized by elevated arterial blood pressure (BP). Hypertension is a major cause of cardiovascular disease and premature death worldwide. High blood pressure is one of the strongest risk factors for ischemic heart disease, stroke, CKD, and dementia. Monitoring high blood pressure globally is important to identify tangible and customized solutions to address high blood pressure. Objective: To assess selected Clinical Chemistry analytes among hypertensive patients on follow-up and non-hypertensive control groups at Wallaga University Referral Hospital, East Wallaga Zone, Oromia, West Ethiopia from May 09 to July 29, 2022. Method: A comparative cross-sectional study was conducted at Wallaga University Referral Hospital, to assess selected Clinical Chemistry analytes among 105 hypertensive patients on follow-up and 105 non hypertensive control groups from May 09 to July 29, 2022. After the study was ethically approved by JUIRB (protocol number IHRPGD/85/), the study participant was interviewed about the socio demographic and anthropometric characteristics features. Then 5ml of the blood sample was collected from study participants who were willing to participate in the study among patients coming to the WURH for their routine follow-up visits during the study period. FBS, serum electrolyte, creatinine, uric acid, and lipid profile level was measured by using a clinical chemistry analyzer Cobas c-311 machine. The Data were analyzed by using Epi data version 4.6 and SPSS version 26 software and results were summarized using means, and percentages and presented using tables. P-value < 0.05 was considered to be significant at a 95% confidence level. Any abnormal laboratory results of study subjects were dispatched and communicated with physicians for better management. Results: The mean age of hypertensive & control study groups were 54.69 ± 12& 44.82 ±12.9 years respectively. Hypertensive patients were significantly lower mean ± SD of serum creatinine, TC, LDL-C, HDL-C, and Sodium, (p < 0.05) respectively; while significantly increased mean ± SD FBS, TG respectively; when compared with non-hypertensive participants and Potassium and uric acid were no statistical significance among both groups. Conclusion & Recommendation: In the present study, we observed that the hypertensive group was at risk for developing Clinical Chemistry alteration with an increased period. Regular measurements of Clinical Chemistry parameters are strongly needed for hypertensive patients